

Summary of 2016 corporate sponsored research exceptions

The original policy was approved by the VCU Board of Visitors on May 15, 2009. Updated versions have been published 11/11/10, 4/5/12, and, most recently, 1/23/17.

The policy has a provision that allows the Vice President for Research and Innovation (VPRI) to review and approve agreements falling outside the norms of the policy. The policy stipulates that the VPRI will notify the Research Development Advisory Council (ReDAC) of his intention to allow an exception. A ReDAC review of the decision will be initiated only upon a request by a majority of ReDAC members. In certain cases, the Vice President for Research may request ReDAC review and recommendation of an agreement outside the norm. To facilitate its review, ReDAC has the responsibility to recruit expert faculty if needed. The VPR is to report to the Faculty Senate on a regular basis concerning review activities and decisions that fall outside the norms of this policy.

(Note: to provide some context, in an average year VCU will negotiate over 500 contracts/agreements that are subject to this policy.)

Summary of Exceptions:

Seventeen (17) requests exception came to the Vice President for Research and Innovation during calendar year 2016.

- 7 requests for extension of confidentiality beyond the policy's stipulation of 5 years after termination of the agreement.

Our policy states that: *...Corporate Research agreements shall be negotiated using the preferred confidentiality terms not to exceed (5) years from the expiration/termination of the agreement or seven (7) years from the date of disclosure of confidential information*

The requests for exception ranged from extensions from 6 to 10 years.

All were approved.

- 9 requests for delays in publication to allow more time for reviews and/or patent protection; requests ranged from 100 – 180 days; requests related to additional time needed for communication with researchers at other study sites and review of patent issues

All were approved

- 1 request to extend the publication delay period for multi-site clinical trials from 18 to 24 months.

This was approved.